References

Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, et al. (2015). P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385: 1198-1205.
Angelo R, Rousseau K, Grant M, Leone-Bay A, & Richardson P (2009). Technosphere® insulin: Defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol 3: 545-554.
Backman P, Adelmann H, Petersson G, & Jones CB (2014). Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther 95: 509-520.
Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. (2000). Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 162: 481-485.
Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, et al. (2011). Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 38: 1071-1080.
Birrell MA, Bonvini SJ, Dubuis E, Maher SA, Wortley MA, Grace MS, et al. (2014). Tiotropium modulates transient receptor potential V1 (TRPV1) in airway sensory nerves: A beneficial off-target effect? J Allergy Clin Immunol 133: 679-687.e679.
Birring SS, Wijsenbeek MS, Agrawal S, van den Berg JWK, Stone H, Maher TM, et al. (2017). A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med 5: 806-815.
Bonvini SJ, & Belvisi MG (2017). Cough and airway disease: The role of ion channels. Pulm Pharmacol Ther 47: 21-28.
Brannan JD, Anderson SD, Perry CP, Freed-Martens R, Lassig AR, Charlton B, et al. (2005). The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 6: 144.
Brown PH, Lenney J, Armstrong S, Ning AC, & Crompton GK (1992). Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists. Eur Respir J 5: 1143-1145.
Buday T, Kovacikova L, Ruzinak R, & Plevkova J (2017). TRPV4 antagonist GSK2193874 does not modulate cough response to osmotic stimuli. Respir Physiol Neurobiol 236: 1-4.
National Ambulatory Medical Care Survey: 2010 Summary Tables [Online] Available from https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2010_namcs_web_tables.pdf. [Accessed: 7 Nov 2018].
Ceglia L, Lau J, & Pittas AG (2006). Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 145: 665-675.
Challoner P, Flora M, Hirst P, Klimowicz M, Newman S, Schaeffler B, et al. Gamma scintigraphy lung deposition comparison of TOBI in the Pari LC Plus nebulizer and the Aerodose inhaler.
Choudry NB, Fuller RW, & Pride NB (1989). Sensitivity of the human cough reflex: effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine. Am Rev Respir Dis 140: 137-141.
Chung KF (2011). Chronic ’cough hypersensitivity syndrome’: a more precise label for chronic cough. Pulm Pharmacol Ther 24: 267-271.
Chung KF, & Pavord ID (2008). Prevalence, pathogenesis, and causes of chronic cough. Lancet 371: 1364-1374.
Cipolla D, & Chan HK (2013). Inhaled antibiotics to treat lung infection. Pharm Pat Anal 2: 647-663.
Conole D, & Keating GM (2014). Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs 74: 377-387.
Corboz MR, Li Z, Malinin V, Plaunt AJ, Konicek DM, Leifer FG, et al. (2017). Preclinical pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil (C16TR), a pulmonary vasodilator prodrug. J Pharmacol Exp Ther 363: 348-357.
de Marco R, Marcon A, Jarvis D, Accordini S, Almar E, Bugiani M, et al. (2006). Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol 117: 1249-1256.
Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, & Nardell E (2013). Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 57: 2613-2619.
Dubus JC, Mely L, Huiart L, Marguet C, Le Roux P, & Reseau de Recherche Clinique en Pneumologie P (2003). Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma. Fundam Clin Pharmacol 17: 627-631.
Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. (2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240.
Empey DW, Laitinen LA, Jacobs L, Gold WM, & Nadel JA (1976). Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 113: 131-139.
Engel T, Heinig JH, Malling HJ, Scharling B, Nikander K, & Madsen F (1989). Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy 44: 220-225.
Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, & Wong SC (2010). Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 105: 323-332.
Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, et al. (2015). Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe (Sheff) 11: 39-48.
Fuller RW, Dixon CM, & Barnes PJ (1985). Bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol (1985) 58: 1080-1084.
Fuller RW, & Jackson DM (1990). Physiology and treatment of cough. Thorax 45: 425-430.
Geller DE, Konstan MW, Smith J, Noonberg SB, & Conrad C (2007). Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 42: 307-313.
Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, & Higgins M (2014). Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care 59:388-398.
Grace MS, Lieu T, Darby B, Abogadie FC, Veldhuis N, Bunnett NW, et al. (2014). The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br J Pharmacol 171: 3881-3894.
Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, et al. (2017). Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Ther Adv Respir Dis 11: 249-260.
Gziut M, MacGregor HJ, Nevell T, Mason T, Laight D, & Shute JK (2013). Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity. Br J Pharmacol 168: 1165-1181.
Hogg J (2004). Peripheral lung remodelling in asthma and chronic obstructive pulmonary disease. Eur Respir J 24: 893-894.
Hoppentocht M, Akkerman OW, Hagedoorn P, Alffenaar JW, van der Werf TS, Kerstjens HA, et al. (2016). Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PLoS One 11: e0149768.
Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, et al. (2009). Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 8: 332-337.
Huckle AW, Fairclough LC, & Todd I (2018). Prophylactic antibiotic use in COPD and the potential anti-inflammatory activities of antibiotics. Respir Care 63:609-619.
Irwin RS, French CL, Chang AB, Altman KW, & Panel* CEC (2018). Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest 153: 196-209.
Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, & Gurniak M (2009). Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 49: 1239-1246.
Johnstone KJ, Chang AB, Fong KM, Bowman RV, & Yang IA (2013). Inhaled corticosteroids for subacute and chronic cough in adults. Cochrane Database Syst Rev: CD009305.
Joos GF, De Swert KO, Schelfhout V, & Pauwels RA (2003). The role of neural inflammation in asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci 992:218-230.
Kamimura M, Izumi S, Hamamoto Y, Morita A, Toyota E, Kobayashi N, et al. (2012). Superiority of nebulized corticosteroids over dry powder inhalers in certain patients with cough variant asthma or cough-predominant asthma. Allergol Int 61: 411-417.
Kanth PM, Alaienia C, & Smaldone GC (2018). Nebulized mannitol, particle distribution, and cough in idiopathic pulmonary fibrosis. Respir Care 63: 1407-1412.
Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, & Lombardi S (2017). Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ 7: 598-608.
Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. (2011). Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 10: 54-61.
Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, & Angyalosi G (2011). Tobramycin Inhalation Powder for P. aeruginosa Infection in Cystic Fibrosis: The EVOLVE Trial. Pediatr Pulmonol 46: 230-238.
Koskela HO, Lake C, Wong K, & Brannan JD (2018). Cough sensitivity to mannitol inhalation challenge identifies subjects with chronic cough. Eur Respir J 51.
Koskela HO, Purokivi MK, Kontra KM, Taivainen AH, & Tukiainen HO (2008). Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clin Exp Allergy 38:1100-1107.
Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. (2008). Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 102: 593-604.
Le Brun PP, de Boer AH, Mannes GP, de Fraiture DM, Brimicombe RW, Touw DJ, et al. (2002a). Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54:25-32.
Le Brun PPH, de Boer AH, Mannes GPM, de Fraı̂ture DMI, Brimicombe RW, Touw DJ, et al. (2002b). Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2: Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 54: 25-32.
Lenney W, Edenborough F, Kho P, & Kovarik JM (2011). Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros 10: 9-14.
Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, et al. (2017). Aerosolized polymyxin B for treatment of respiratory tract infections: determination of pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin B against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 61.
Lowry RH, Wood AM, & Higenbottam TW (1988). Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci (Lond) 74: 373-376.
Mazurek H, Chiron R, Kucerova T, Geidel C, Bolbas K, Chuchalin A, et al. (2014). Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatr Pulmonol 49: 1076-1089.
Mazzone SB, & Undem BJ (2016). Vagal afferent innervation of the airways in health and disease. Physiol Rev 96: 975-1024.
McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. (2010). Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55: 1915-1922.
Midgren B, Hansson L, Karlsson JA, Simonsson BG, & Persson CG (1992). Capsaicin-induced cough in humans. Am Rev Respir Dis 146: 347-351.
Minasian C, Wallis C, Metcalfe C, & Bush A (2008). Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 43: 1078-1084.
Morice AH (2004). The diagnosis and management of chronic cough. Eur Respir J 24: 481.
Morice AH, Faruqi S, Wright CE, Thompson R, & Bland JM (2011). Cough hypersensitivity syndrome: a distinct clinical entity. Lung 189: 73-79.
Morice AH, Kastelik JA, & Thompson R (2001). Cough challenge in the assessment of cough reflex. Br J Clin Pharmacol 52: 365-375.
Mutolo D, Cinelli E, Iovino L, Pantaleo T, & Bongianni F (2016). Downregulation of the cough reflex by aclidinium and tiotropium in awake and anesthetized rabbits. Pulm Pharmacol Ther 38: 1-9.
Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. (2003). Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124: 360-366.
Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, et al. (2007). Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 13: 1246-1252.
Pilcer G, & Amighi K (2010). Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392: 1-19.
Purokivi M, Koskela H, & Kontra K (2013). Determinants of asthma control and quality of life in stable asthma: evaluation of two new cough provocation tests. Clin Respir J 7: 253-260.
Quattrin T, Belanger A, Bohannon NJ, Schwartz SL, & Exubera Phase IIISG (2004). Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27: 2622-2627.
Richards R, Haas A, Simpson S, Britten A, Renwick A, & Holgate S (1988). Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways. Thorax 43: 611-616.
Rosenstock J, Franco D, Korpachev V, Shumel B, Ma Y, Baughman R, et al. (2015). Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naive Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care 38: 2274-2281.
Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, & Collard HR (2011). Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 16: 969-975.
Satia I, Badri H, Al-Sheklly B, Smith JA, & Woodcock AA (2016). Towards understanding and managing chronic cough. Clin Med (Lond) 16: s92-s97.
Scheinberg P, & Shore E (2005). A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 127:1420-1426.
Schuster A, Haliburn C, Doring G, & Goldman MH (2013). Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 68: 344-350.
Shim C, & Williams MH, Jr. (1987a). Cough and wheezing from beclomethasone aerosol. Chest 91:207-209.
Shim CS, & Williams MH, Jr. (1987b). Cough and wheezing from beclomethasone dipropionate aerosol are absent after triamcinolone acetonide. Ann Intern Med 106: 700-703.
Sommerwerck U, Virella-Lowell I, Angyalosi G, Viegas A, Cao W, & Debonnett L (2016). Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Curr Med Res Opin 32: 1789-1795.
Sterling GM, & Batten JC (1969). Effect of aerosol propellants and surfactants on airway resistance. Thorax 24: 228-231.
Ternesten-Hasseus E, Johansson EL, & Millqvist E (2015). Cough reduction using capsaicin. Respir Med 109: 27-37.
van den Borst B, Gosker HR, Zeegers MP, & Schols AM (2010). Pulmonary function in diabetes: A metaanalysis. Chest 138: 393-406.
Velkov T, Abdul Rahim N, Zhou QT, Chan H-K, & Li J (2015). Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Adv Drug Deliv Rev 85: 65-82.
Westerman EM, De Boer AH, Le Brun PPH, Touw DJ, Roldaan AC, Frijlink HW, et al. (2007). Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study. J Cyst Fibros 6: 284-292.
Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, & Heijerman HGM (2004). Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 3: 23-28.
Wex E, & Bouyssou T (2015). Olodaterol attenuates citric acid-induced cough in naive and ovalbumin-sensitized and challenged guinea pigs. PLoS One 10:e0119953.
Widdicombe JG (1995). Neurophysiology of the cough reflex. Eur Respir J 8: 1193.
Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, & Crompton GK (1995). Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 8: 590-592.
Wong CH, & Morice AH (1999). Cough threshold in patients with chronic obstructive pulmonary disease. Thorax 54: 62-64.
Zhou QT, Leung SS, Tang P, Parumasivam T, Loh ZH, & Chan HK (2015). Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev 85: 83-99.
Zwozdziaka A, Gini M, & Samek L (2017). Implications of the aerosol size distribution modal structure of trace and major elements on human exposure, inhaled dose and relevance to the PM2.5 and PM10 metrics in a European pollution hotspot urban area J Aerosol Sci 103: 38-52.